Wells Fargo
QNTM

Wells Fargo’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Wells Fargo’s Portfolio QNTM Stock Details QNTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$907 Buy
250
+150
+150% +$708 ﹤0.01% 6465
2026
Q1 		$477 Buy
+100
New +$451 ﹤0.01% 6399

Other funds holding QNTM

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Wells Fargo's QNTM Position: Q2 2026 in Review

Wells Fargo increased its Quantum Biopharma Class B Subordinate Voting Shares (QNTM) stake by 150% in Q2 2026, buying an estimated $708 and bringing the position to 250 shares worth $907. The position accounts for ﹤0.01% of the portfolio, ranked #6465.

Wells Fargo first reported a position in QNTM in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold QNTM as of Q2 2026.

  • Wells Fargo held 250 shares of Quantum Biopharma Class B Subordinate Voting Shares worth $907 as of Q2 2026.
  • Wells Fargo bought 150 Quantum Biopharma Class B Subordinate Voting Shares shares in Q2 2026, an estimated $708.
  • Quantum Biopharma Class B Subordinate Voting Shares made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6465 holding.
  • Wells Fargo first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.